Skip to main content
OpenTrials

Clinical trial condition

Relapsing-Remitting Multiple Sclerosis

Explore clinical trials studying Relapsing-Remitting Multiple Sclerosis. Study availability and eligibility vary by location and protocol.

97 public trials 4 recruiting studies
Refine in advanced search Browse all conditions

Relapsing-Remitting Multiple Sclerosis trial results

Recruiting

The HIt HArd and hiT Early in Multiple Sclerosis Trial

NCT07517185

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Falu Lasarett, Neurologen Falun, Sweden
  • Gävle sjukhus, Neurologmottagningen Gävle, Sweden
  • Centralsjukhuset Karlstad, Neurologi och Rehabiliteringskliniken Karlstad, Sweden
  • Uppsala University Hospital Uppsala, Sweden
View Trial Details
Recruiting

RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.

NCT05758831

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Hospices Civils de Lyon Hôpital Neurologique Pierre Wertheimer Lyon, Bron, France
  • CHRU de Brest - Hôpital la Cavale Blanche Brest, France
  • Centre Hospitalier Universitaire de Caen Caen, France
  • Centre Hospitalier de Pontoise - GHT NOVO Cergy-Pontoise, France
View all 23 locations
View Trial Details
Active, not recruiting

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT05123703

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • UC San Diego La Jolla, California, United States
  • Children's Hospital Colorado Aurora, Colorado, United States
  • Children's National Hospital Washington D.C., District of Columbia, United States
  • Johns Hopkins Medicine Baltimore, Maryland, United States
View all 71 locations
View Trial Details
Active, not recruiting

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

NCT05090371

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +10 more
Locations
  • Alabama Neurology Associates PC Birmingham, Alabama, United States
  • North Central Neurology Associates PC Cullman, Alabama, United States
  • Radiant Research Chandler Chandler, Arizona, United States
  • Arizona Neuroscience Research LLC Phoenix, Arizona, United States
View all 43 locations
View Trial Details
Active, not recruiting

Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis

NCT04530318

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Hospital Moisés Broggi L'Hospitalet de Llobregat, Barcelona, Spain
  • Hospital Universitari de Bellvitge L'Hospitalet de Llobregat, Barcelona, Spain
  • Hospital Clínic de Barcelona Barcelona, Spain
  • Hospital de Sant Pau Barcelona, Spain
View Trial Details
Completed

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT02283853

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Boston Children's Hospital Boston, Massachusetts, United States
  • The Rector and Visitors of the University of Virginia Charlottesville, Virginia, United States
  • Universitair Kinderziekenhuis Koningin Fabiola Brussels, Belgium
  • Universitair Ziekenhuis Ghent Ghent, Belgium
View all 62 locations
View Trial Details

Related conditions